期刊文献+

Advances in Multidisciplinary Treatment of Rectal Cancer 被引量:1

Advances in Multidisciplinary Treatment of Rectal Cancer
下载PDF
导出
摘要 To summarize the advances in the multidisciplinarytreatment of rectal cancer and to analyze the existing problems anddevelopment prospects.The full text database retrieval system ofMEDLINE and the periodicals of CHKD were searched.The words'rectal cancer,diagnosis,surgery,chemotherapy,radiotherapy,targeted therapy,analysis' were used as key words for retrievalof literature concerning the values and clinical significance ofrectal cancer multidisciplinary treatment from January,2000 toDecember,2007.Thirty papers were selected,of which 26 wereused in analysis at last.Accurate preoperative staging of rectalcancer is a key factor in the multidisciplinary and comprehensivetreatment of patients.A new therapy which is combined withradical operation can reduce the rate of local recurrence,prolongsurvival time,and particularly,promote the rate of sphincterpreservation.Radical surgery combined with adjuvant therapy isstill recognized as standard treatment modality for the patientswith rectal cancer in stage Ⅱ-Ⅲ.Total removal of resectablemetastases followed by prompt standard adjuvant therapy mayextend survival time.The introduction of new chemical drugs,drugs of targeting therapy,and a regimen of combination therapymay improve outcomes in treatment for rectal cancer patients.Atreatment standard for rectal cancer patients needs to be activelypursued.Compared with colon cancer patients,there has notbeen sufficient evidence to confirm that the total survival rate ofrectal cancer patients after multidisciplinary and comprehensivetreatments has been improved;therefore,it needs to be furtherstudied. To summarize the advances in the multidisciplinary treatment of rectal cancer and to analyze the existing problems and development prospects. The full text database retrieval system of MEDLINE and the periodicals of CHKD were searched. The words "rectal cancer, diagnosis, surgery, chemotherapy, radiotherapy, targeted therapy, analysis" were used as key words for retrieval of literature concerning the values and clinical significance of rectal cancer multidisciplinary treatment from January, 2000 to December, 2007. Thirty papers were selected, of which 26 were used in analysis at last. Accurate preoperative staging of rectal cancer is a key factor in the multidisciplinary and comprehensive treatment of patients. A new therapy which is combined with radical operation can reduce the rate of local recurrence, prolong survival time, and particularly, promote the rate of sphincter preservation. Radical surgery combined with adjuvant therapy is still recognized as standard treatment modality for the patients with rectal cancer in stage Ⅱ-Ⅲ. Total removal of resectable metastases followed by prompt standard adjuvant therapy may extend survival time. The introduction of new chemical drugs, drugs of targeting therapy, and a regimen of combination therapy may improve outcomes in treatment for rectal cancer patients. A treatment standard for rectal cancer patients needs to be actively pursued. Compared with colon cancer patients, there has not been sufficient evidence to confirm that the total survival rate of rectal cancer patients after multidisciplinary and comprehensive treatments has been improved; therefore, it needs to be further studied.
出处 《Clinical oncology and cancer researeh》 CAS CSCD 2009年第5期367-373,共7页
关键词 rectal cancer SURGERY CHEMOTHERAPY RADIOTHERAPY analysis. 直肠癌 多学科 治疗
  • 相关文献

参考文献2

二级参考文献23

  • 1Tio TL, Coene PP, van Delden OM, et al. Colorectal carcinoma:preoperative TNM classification with endosonography[J]. Radiology, 1991, 179(1): 165~170.
  • 2Kimmey MB, Martin RW, Haggitt RC, et al. Histologic correlates of gastrointestinal ultrasound images [J]. Gastroenterology, 1989,96(2 pt 1): 433~441.
  • 3Napoleon B, Pujol B, Berger F, et al. Accuracy of endosonography in the staging of rectal cancer treated by radiotherapy[J]. BrJ Surg, 1991, 78(7): 785~788.
  • 4Katsura Y, Yamada K, Ishizawa T, et al. Endorectal ultrasonography for the assessment of wall invasion and lymph node metastasis in rectal cancer[J]. Dis Colon Rectum, 1992, 35(4): 362~368.
  • 5Heriot AG, Grundy A, Kumar D. Preoperative staging of rectal carcinoma[J]. BrJ Surg, 1999, 86(1): 17~28.
  • 6Thoeni RF. Colorectal cancer. Radiological staging[J]. Radiol Clin North Am, 1997, 35(2): 457~485.
  • 7Hulsmans FJ, Tio TL, Fockens P, et al. Assessment of tumor infiltration depth in rectal cancer with transrectal sonography:caution is necessary[J]. Radiology, 1994, 190(3): 715~720.
  • 8Heintz A, Mildenberger P, Georg M, et al. Endoscopic ultrasonography in the diagnosis of regional lymph nodes in esophageal and gastric cancer-results of studies in vitro[J]. Endoscopy, 1993, 25(3): 231~235.
  • 9Roman S,Cenni JC,Roy P,et al.Value of rectal ultrasound in predicting staging and outcome in patients with rectal adenocarcinoma[J].Dis Colon Rectum,2004,47(8):1323 ~ 1330
  • 10Drudi FM,Raffetto N,De Rubeis M,et al.TRUS staging and follow-up in patients with anal canal cancer[J].Radiol Med(Torino),2003,106(4):329~337

共引文献11

同被引文献28

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
  • 2Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer, 2006, 42(14): 2212-2221.
  • 3Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases[J]. Eur J Cancer, 2009, 45(17): 2947-2959.
  • 4Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J]. Ann Surg, 2005, 241(5): 722-724.
  • 5Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous eolorectal liver metastasis[J]. Ann Surg Oncol, 2007, 14(2): 786-794.
  • 6Abdalla EK. Commentary: Radiofrequency ablation for eolorectal liver metastases: do not blame the biology when it is the technology[J]. Am J Surg, 2009, 197(6): 737-739.
  • 7Falcone A, Ricci S, Brunetti I, et al. Phase Ⅲ trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusianal fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J]. J Clin Oncol, 2007, 25(13): 1670-1676.
  • 8Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinie acid, 5-tluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) asfirst-line treatment in metastatic colorectal cancer (MCC): a multicenlre randomised phase III trial from the Hellenic Oncology Research Group (HORG)[J]. Br J Cancer, 2006, 94(6): 798-805.
  • 9Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis[J]. J Natl Cancer Inst, 2011, 103(1): 21-30.
  • 10Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial[J]. Lancet Oncol, 2010, 11(1): 38-47.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部